Search results for "estrogen"

showing 10 items of 530 documents

Zymographic detection and clinical correlations of MMP-2 and MMP-9 in breast cancer sera.

2004

Matrix metalloproteinases, in particular the gelatinases MMP-2 and MMP-9, have received great attention in recent years as putative tumour markers for clinical applications. The main reason for the observed interest is their easy detection in body fluids. Moreover, recent evidence has shown multiple functions of MMPs, rather than simply degrading ECM, which include the mobilisation of growth factors and processing of surface molecules. Several authors have reported increased levels of MMPs in a number of cancers, but clinical correlations in breast cancer are still fragmentary. Thus, the aim of the present research was to investigate the activity levels of circulating gelatinases in the ser…

OncologyCancer Researchmedicine.medical_specialtyGelatinasesmatrix metalloproteinaseReceptor ErbB-2gelatin zymographyMammary glandGelatinase ABreast NeoplasmsBiologyMatrix metalloproteinaseBreast cancerbreast cancerInternal medicineProgesterone receptormedicineBiomarkers TumorGelatinaseHumansSettore BIO/06 - Anatomia Comparata E CitologiaLymph nodeMolecular and Cellular Pathologymatrix metalloproteinasesclinic correlationsmedicine.diseasePrognosismedicine.anatomical_structureEndocrinologyOncologyMatrix Metalloproteinase 9Receptors EstrogenLymphatic MetastasisMatrix Metalloproteinase 2FemaleReceptors ProgesteroneBritish journal of cancer
researchProduct

Targeting breast cancer initiating cells: advances in breast cancer research and therapy

2014

Over the past 10 years there have been significant advances in our understanding of breast cancer and the important roles that breast cancer initiating cells (CICs) play in the development and resistance of breast cancer. Breast CICs endowed with self-renewing and tumor-initiating capacities are believed to be responsible for the relapses which often occur after various breast cancer therapies. In this review, we will summarize some of the key developments in breast CICs which will include discussion of some of the key genes implicated: estrogen receptor (. ER), HER2, BRCA1, TP53, PIK3CA, RB, P16INK1 and various miRs as well some drugs which are showing promise in targeting CICs. In additio…

OncologyCancer Researchmedicine.medical_specialtyKey genesmedicine.medical_treatmentEstrogen receptorAntineoplastic AgentsBreast NeoplasmsMiRCancer stem cells; ER; HER2; Hormonal therapy; MiRs; Targeted therapy; Therapy resistanceTargeted therapyMiRsTargeted therapyBreast cancerCancer stem cellInternal medicineHER2GeneticsmedicineHumansTreatment resistanceskin and connective tissue diseasesMolecular Biologybusiness.industryCancer stem cellsTherapy resistanceProteinsmedicine.diseaseClinical researchERNeoplastic Stem CellsMolecular MedicineHormonal therapyFemalebusinessHormonal therapyCancer stem cells HER2 ER miRs Targeted therapy Hormonal therapy Therapy resistance
researchProduct

The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer

2015

Around 70% of breast cancers express the estrogen receptor α (ERα) and depend on estrogen for growth, survival and disease progression. The presence of hormone sensitivity is usually associated with a favorable prognosis. Use of adjuvant anti-endocrine therapy has significantly decreased breast cancer mortality in patients with early-stage disease, and anti-endocrine therapy also plays a central role in the treatment of advanced stages. However a subset of hormone receptor-positive breast cancers do not benefit from anti-endocrine therapy, and nearly all hormone receptor-positive metastatic breast cancers ultimately develop resistance to anti-hormonal therapies. Despite new insights into me…

OncologyCancer Researchmedicine.medical_specialtyKinasebusiness.industryBortezomibmedicine.drug_classEstrogen receptormedicine.diseaseBreast cancerOncologyEstrogenInternal medicineProteasome inhibitormedicineskin and connective tissue diseasesbusinessProtein kinase BPI3K/AKT/mTOR pathwaymedicine.drugInternational Journal of Cancer
researchProduct

Letter to the Editor regarding the paper by Aurilio et al., A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth f…

2014

Sir,We have read with great interest the article in press ofAurilio et al., A meta-analysis of oestrogen receptor, pro-gesterone receptor and human epidermal growth factorreceptor 2 discordance between primary breast cancerand metastases (http://dx.doi.org/10.1016/j.ejca.2003.10.004), which will appear in Eur J Cancer. In the paper,the Authors have performed a meta-analysis of the stud-ies published in the literature concerning the discor-dance rate in oestrogen receptor (ER), progesteronereceptor (PgR) and HER2 status between primarytumour and corresponding relapse. It is well known thata considerable controversy concerns the issue of hor-mone receptors (HRs) expression as well as HER2 sta…

OncologyCancer Researchmedicine.medical_specialtyPathologyLetter to the editorBreast NeoplasmsSettore MED/08 - Anatomia PatologicaErbB-2breast cancer metastases oestrogen receptor human epidermal growth factor receptor 2Internal medicineProgesterone receptorReceptorsmedicineHumansOestrogen receptorskin and connective tissue diseasesReceptorProgesteronebusiness.industryCancermedicine.diseaseEstrogenRegimenOncologyLOCALLY RECURRENT HORMONE-RECEPTOR HER2 STATUS IMPACTMeta-analysisBreast Neoplasms; Female; Humans; Receptor ErbB-2; Receptors Estrogen; Receptors ProgesteroneImmunohistochemistryFemalebusinessReceptor
researchProduct

Immunoglobulin Kappa C Has Independent Prognostic Significance in Node-Negative Breast Cancer.

2009

Abstract Background: Utilizing microarray based gene-expression analysis of fresh-frozen tissue we could recently demonstrate the prognostic impact of a B cell metagene in node-negative breast cancer (Cancer Res 68: 5405-5413, 2008). In the present study we investigated the prognostic significance of immunoglobulin kappa c (IGKC) in formalin-fixed paraffin embedded (FFPE) breast cancer specimens of 363 node-negative breast cancer patients which were not treated in the adjuvant setting.Methods: RT-PCR was used to analyze mRNA expression of IGKC in FFPE tissue of 363 patients with node-negative breast cancer. Additionally to IGKC we examined the prognostic impact of age, histological grade, t…

OncologyCancer Researchmedicine.medical_specialtyUnivariate analysisPathologyMicroarraybusiness.industrymedicine.medical_treatmentEstrogen receptorCancermedicine.diseaseBreast cancermedicine.anatomical_structureOncologyInternal medicineProgesterone receptormedicinebusinessAdjuvantB cellCancer Research
researchProduct

Do multiple oestrogen receptor assays give significant additional information for the management of breast cancer?

1989

In 101 breast cancer patients, measurement of oestrogen receptor status in multiple biopsies across a tumour reveals a highly significant difference in the proportion of patients remaining either disease-free (P less than 0.04) or alive (P less than 0.005), when those with uniformly receptor positive (++) primary tumours are matched with clinically comparable patients whose tumours were homogeneously receptor negative (--). Mean follow-up time was 85 months. The prognostic value of this discriminant is particularly striking in the 53 patients with involved nodes at presentation. Of these, 13 were (++) and seven remain alive of whom six are disease-free, whereas 24 of the 29 (--) patients ar…

OncologyCancer Researchmedicine.medical_specialtymedicine.drug_classMammary glandBreast NeoplasmsBiologyBreast cancerInternal medicineClinical informationmedicineHumansOestrogen receptorReceptorSignificant differencemedicine.diseasePrognosisMenopauseEndocrinologymedicine.anatomical_structureOncologyReceptors EstrogenEstrogenFemaleMenopauseResearch ArticleBritish journal of cancer
researchProduct

Nuclear and cytoplasmic interaction of pRb2/p130 and ER-β in MCF-7 breast cancer cells

2006

Estrogens exhibit important biological functions and influence several pathological processes of hormone-dependent diseases. The biological actions of estrogens require their interaction with two estrogen receptors (ER-alpha and ER-beta), which are ligand-dependent transcription factors. ER-alpha and ER-beta exhibit distinct tissue expression patterns as well as show different patterns of gene regulation. In addition, it has been suggested that ER-beta works as a counter partner of ER-alpha through inhibition of the transactivating functions of ER-alpha. For instance, ER-beta seems to play a different role in breast tumorigenesis than ER-alpha, as ER-beta decreased expression in breast canc…

OncologyCytoplasmmedicine.medical_specialtyMolecular Sequence DataEstrogen receptorBreast NeoplasmsEstrogen receptorsmedicine.disease_causeBreast cancerBreast cancerCancer stem cellCell Line TumorInternal medicinemedicineEstrogen Receptor betaHumansImmunoprecipitationGene silencingAmino Acid SequenceTranscription factorBreast cancer; Estrogen receptors; Estrogens; pRb2/130Cell NucleusRegulation of gene expressionRetinoblastoma-Like Protein p130business.industryEstrogensHematologymedicine.diseaseOncologyMCF-7Cancer researchbusinessCarcinogenesispRb2/130
researchProduct

Associations between aromatase CYP19 rs10046 polymorphism and breast cancer risk: from a case-control to a meta-analysis of 20,098 subjects.

2012

Lifetime exposure to estrogen is a factor that plays an important role in the pathogenesis and progression of breast cancer. Genetic variants in genes of the biosynthesis and metabolism of estrogen have been associated with breast cancer risk. Among them, the CYP19 gene encodes for aromatase, the enzyme that catalyzes the conversion of androgens to estrogens. The rs10046 polymorphism on the CYP19 gene has been related to levels of circulating estradiol and to the estradiol/testosterone ratio. To date, epidemiological studies of rs10046 have been performed in different populations with contradictory results. In the present study, we have conducted a case-control analysis (522 cases and 1221 …

OncologyEpidemiologylcsh:MedicineBreast TumorsAromataselcsh:ScienceAged 80 and overMultidisciplinarybiologyObstetrics and GynecologyMiddle AgedOncologyMeta-analysisMedicineFemaleCancer EpidemiologyResearch ArticleAdultmedicine.medical_specialtyAdolescentmedicine.drug_classBreast NeoplasmsPolymorphism Single NucleotideYoung AdultBreast cancerAromataseInternal medicineGenetic modelBreast CancermedicineGeneticsHumansGenetic Predisposition to DiseaseAlleleBiologyAgedPopulation Biologylcsh:RCase-control studyReproducibility of ResultsCancers and NeoplasmsOdds ratiomedicine.diseaseEndocrinologyEstrogenCase-Control Studiesbiology.proteinGenetic PolymorphismWomen's Healthlcsh:QPopulation GeneticsPLoS ONE
researchProduct

Basic and Clinical Relevance of Hormonal Influence in Breast Cancer

1990

In the Federal Republic of Germany breast cancer has a leading place among malignant tumors in women. Genital and breast cancers account for 32% of all female deaths from malignant neoplasias. The distribution of types of cancer is as follows: breast 52%, uterine cervix 9%, corpus uteri 4.5%, adnexae 19%, and other sex organs 15.5% (Maas and Sachs 1972; Schmidt-Matthiesen 1975, Vorherr 1980). Besides general epidemiological factors such as geographical distribution, dietary factors, age distribution, familial disposition, and socioeconomic influences, possible hormonal components are discussed in connection with the etiology of breast cancer (Fischedick and Lux 1977; Henderson et al. 1974; …

OncologyGynecologymedicine.medical_specialtybusiness.industryIncidence (epidemiology)Estrogen receptorCancermedicine.diseaseMenopauseBreast cancerInternal medicineEtiologyMedicineSex organRisk factorbusiness
researchProduct

Risk prediction for estrogen receptor-specific breast cancers in two large prospective cohorts

2018

Source at https://doi.org/10.1186/s13058-018-1073-0. Licensed CC BY-NC-ND 4.0. Background: Few published breast cancer (BC) risk prediction models consider the heterogeneity of predictor variables between estrogen-receptor positive (ER+) and negative (ER-) tumors. Using data from two large cohorts, we examined whether modeling this heterogeneity could improve prediction. Methods: We built two models, for ER+ (ModelER+) and ER- tumors (ModelER-) , respectively, in 281,330 women (51% postmenopausal at recruitment) from the European Prospective Investigation into Cancer and Nutrition cohort. Discrimination (C-statistic) and calibration (the agreement between predicted and observed tumor risks)…

OncologyHORMONE-REPLACEMENT THERAPYmedicine.medical_treatmentWHI0302 clinical medicineBreast cancerRisk FactorsEstrogen receptor030212 general & internal medicineProspective StudiesProspective cohort study2. Zero hungerIncidenceHormone replacement therapy (menopause)Middle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensPrognosisRisk prediction3. Good healthEuropean Prospective Investigation into Cancer and NutritionMenopausePOSTMENOPAUSAL WOMENReceptors EstrogenPLUS PROGESTIN030220 oncology & carcinogenesisCohortFemaleRisk assessmentResearch Articlemedicine.medical_specialtyMODELSAntineoplastic AgentsBreast NeoplasmsEstrògenslcsh:RC254-282Models BiologicalRisk AssessmentVALIDATIONCàncer de mamaMAMMOGRAPHY03 medical and health sciencesBreast cancerInternal medicinemedicineHumansOncology & CarcinogenesisCancer och onkologiVDP::Medical disciplines: 700::Clinical medical disciplines: 750::Oncology: 762business.industryMORTALITYKirurgiProspective cohortmedicine.diseaseEstrogenVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Onkologi: 762Cancer and OncologySurgerybusinessEPIC1112 Oncology And CarcinogenesisBody mass indexFollow-Up StudiesBreast Cancer Research : BCR
researchProduct